Your browser doesn't support javascript.
loading
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
Berry, Catherine; Pavot, Vincent; Anosova, Natalie G; Kishko, Michael; Li, Lu; Tibbitts, Tim; Raillard, Alice; Gautheron, Sylviane; Cummings, Sheila; Bangari, Dinesh S; Kar, Swagata; Atyeo, Caroline; Deng, Yixiang; Alter, Galit; Gutzeit, Cindy; Koutsoukos, Marguerite; Chicz, Roman M; Lecouturier, Valerie.
Afiliación
  • Berry C; Sanofi, Vaccines R&D, Marcy l'Etoile, France.
  • Pavot V; Sanofi, Vaccines R&D, Marcy l'Etoile, France.
  • Anosova NG; Sanofi, Vaccines R&D, Cambridge, MA, USA.
  • Kishko M; Sanofi, Vaccines R&D, Cambridge, MA, USA.
  • Li L; Sanofi, Vaccines R&D, Cambridge, MA, USA.
  • Tibbitts T; Sanofi, Vaccines R&D, Cambridge, MA, USA.
  • Raillard A; Sanofi, Vaccines R&D, Marcy l'Etoile, France.
  • Gautheron S; Sanofi, Vaccines R&D, Marcy l'Etoile, France.
  • Cummings S; Sanofi, Framingham, MA, USA.
  • Bangari DS; Sanofi, Framingham, MA, USA.
  • Kar S; BIOQUAL Inc, Rockville, MD, USA.
  • Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Deng Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Gutzeit C; GSK, Rixensart, Belgium.
  • Koutsoukos M; GSK, Wavre, Belgium.
  • Chicz RM; Sanofi, Vaccines R&D, Cambridge, MA, USA.
  • Lecouturier V; Sanofi, Vaccines R&D, Marcy l'Etoile, France. valerie.lecouturier@sanofi.com.
Commun Med (Lond) ; 3(1): 75, 2023 May 26.
Article en En | MEDLINE | ID: mdl-37237062
SARS-CoV-2 has changed over time, resulting in different forms of the virus called variants. These variants compromise the protection offered by the COVID-19 vaccines, which trigger an immune response against the viral Spike protein that allows the virus to attach and infect human cells, since their spike proteins are different. Here, we developed and tested a vaccine containing two different Spike proteins, one from the original Wuhan strain and another from the Beta variant. In macaques, the vaccine leads to the production of antibodies able to stop all variants tested from infecting human cells, including Omicron, with stable levels over one year. In hamsters, the vaccine protected against infection with the ancestral virus and the Alpha and Beta variants. Our findings have important implications for vaccine control of existing and future SARS-CoV-2 variants of concern.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido